Dual Antiplatelet Therapy Duration After Multivessel Optimal Intravascular Ultrasound-Guided Percutaneous Coronary Intervention

Abstract

not been adequately reported in real clinical practice after these clinical trials. Moreover, the majority of patients enrolled in the clinical trials evaluating short DAPT had relatively low coronary anatomic complexity, and the prevalence of complex lesions such as multivessel disease was low. 1-6 There is a scarcity of data evaluating contemporary S everal randomized controlled trials have suggested that the strategy of shorter duration of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitors monotherapy reduces major bleeding without increasing cardiovascular events after percutaneous coronary intervention (PCI). 1-6 However, actual DAPT durations have